{"gene":"HDAC9","run_date":"2026-06-10T01:55:21","timeline":{"discoveries":[{"year":2001,"finding":"HDAC9 (and its isoform HDAC9a) contains an HDAC catalytic domain and Flag-tagged HDAC9/HDAC9a possess deacetylase activity in vitro. HDAC9 has multiple alternatively spliced isoforms, including MITR which lacks the catalytic domain. HDAC9 and HDAC9a repress MEF2-mediated transcription.","method":"Cloning, in vitro deacetylase activity assay, reporter gene assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct in vitro enzymatic assay with Flag-tagged protein plus transcriptional repression assay, single lab but multiple orthogonal methods","pmids":["11535832"],"is_preprint":false},{"year":1999,"finding":"MITR (an HDAC9 isoform lacking a catalytic domain) binds directly to the MADS/MEF-2 domain of MEF2 proteins (MEF2D and MEF2A) but not to SRF, and represses MEF2-dependent transcription by recruiting HDAC1.","method":"Yeast two-hybrid screen, functional transcription assay, direct binding experiments in Xenopus embryo model","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 / Moderate — yeast two-hybrid plus functional repression assay, HDAC1 recruitment demonstrated, replicated in orthologous system","pmids":["10487760"],"is_preprint":false},{"year":2001,"finding":"MITR (HDAC9 isoform) interacts with the transcriptional corepressor CtBP through a conserved P-X-D-L-R motif. Mutation of this motif abolishes CtBP interaction and impairs (but does not eliminate) MEF2 transcriptional repression. Residual repressive activity of CtBP-binding mutants is attributable to association with other HDAC family members, revealing CtBP-dependent and -independent mechanisms for transcriptional repression by MITR.","method":"Co-immunoprecipitation, mutagenesis of CtBP-binding motif, reporter gene transcription assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — mutagenesis plus Co-IP plus functional reporter assay, multiple orthogonal methods in single study","pmids":["11022042"],"is_preprint":false},{"year":2001,"finding":"MITR (HDAC9 isoform) is a signal-responsive inhibitor of myogenesis. Phosphorylation of Ser-218 and Ser-448 stimulates binding of 14-3-3 to MITR, disrupts MEF2:MITR interactions, alters nuclear distribution of MITR, and relieves repression of muscle-specific gene expression. A Ser→Ala double mutant acts as a potent repressor of myogenesis, confirming these serines as the regulatory switch.","method":"Site-directed mutagenesis, co-immunoprecipitation, immunofluorescence localization, reporter gene assay, myogenic differentiation assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — mutagenesis plus Co-IP plus localization plus functional differentiation assay, multiple orthogonal methods","pmids":["11390982"],"is_preprint":false},{"year":2009,"finding":"HDAC9 deletion in T regulatory cells (Tregs) leads to increased expression of HSP70, and immunoprecipitation experiments revealed a direct interaction between HSP70 and Foxp3. Inhibition of HSP70 reduced the suppressive functions of HDAC9-/- Tregs, while Tregs overexpressing HSP70 had increased suppressive functions. HDAC9-/- mice were resistant to colitis development.","method":"HDAC9 knockout mice, Treg transfer experiments, co-immunoprecipitation (HSP70–Foxp3 interaction), HSP70 inhibition/overexpression assays","journal":"Gastroenterology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic KO with defined cellular phenotype plus Co-IP plus functional rescue experiments, multiple orthogonal methods","pmids":["19879272"],"is_preprint":false},{"year":2015,"finding":"HDAC9 promotes glioblastoma tumor formation via interaction with TAZ (a Hippo pathway effector). Knockdown of HDAC9 decreased TAZ expression, and overexpression of TAZ in HDAC9-knockdown cells abrogated the effects of HDAC9 silencing on proliferation and tumor formation, placing HDAC9 upstream of TAZ in the EGFR signaling pathway.","method":"HDAC9 knockdown, TAZ overexpression rescue, in vitro proliferation assay, in vivo tumor formation assay","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis via rescue experiment plus in vivo validation, single lab","pmids":["25760078"],"is_preprint":false},{"year":2015,"finding":"HDAC9 inhibits osteoclast differentiation and bone resorption through a mutual suppression loop with PPARγ/RANKL signaling. HDAC9 forms a negative regulatory loop: PPARγ and NF-κB suppress HDAC9 expression, while HDAC9 inhibits PPARγ activity in synergy with SMRT/NCoR corepressors. HDAC9 knockout mice exhibit elevated bone resorption and lower bone mass, and bone marrow transplantation confirms the effect is intrinsic to hematopoietic lineage.","method":"HDAC9 knockout mice, bone marrow transplantation, ex vivo osteoclast differentiation assay, HDAC9 overexpression, co-repressor interaction assays","journal":"Molecular endocrinology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO with bone phenotype, bone marrow transplantation epistasis, mechanistic co-repressor interaction, multiple orthogonal methods","pmids":["25793404"],"is_preprint":false},{"year":2011,"finding":"MITR (HDAC9c isoform) promotes osteogenesis and inhibits adipogenesis of mesenchymal stem cells by directly interacting with PPARγ-2 in the nucleus of osteoblasts, thereby interrupting PPARγ-2 transcriptional activity and preventing adipogenesis.","method":"EZH2-ChIP-on-chip to identify MITR as target, functional differentiation assays, co-immunoprecipitation/interaction studies with PPARγ-2","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP assay plus functional differentiation assay plus interaction studies, single lab","pmids":["21247904"],"is_preprint":false},{"year":2015,"finding":"Dach2 and Hdac9 act collaboratively as activity-regulated transcriptional co-repressors to inhibit reinnervation of denervated mouse skeletal muscle. They inhibit denervation-dependent induction of Myog and Gdf5 gene expression. Myog and Gdf5 appear to stimulate reinnervation through parallel pathways (Myog does not regulate Gdf5 transcription).","method":"Dach2 and Hdac9 loss-of-function in mouse skeletal muscle, gene expression analysis, epistasis experiments","journal":"Development","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic loss-of-function with defined reinnervation phenotype plus epistasis, single lab","pmids":["26483211"],"is_preprint":false},{"year":2017,"finding":"HDAC9 regulates hepatic gluconeogenesis by deacetylating FoxO1 (post-translational modification). HDAC9 also regulates gluconeogenic transcription factors PGC-1α, CREB, and GR by altering gene expression via the FoxO1 deacetylation pathway. PGC-1α, CREB and GR are upregulated in response to HDAC9 via FoxO1 deacetylation, and HDAC9-FoxO1 signaling is induced by HCV infection to exaggerate gluconeogenesis.","method":"Deacetylation assay of FoxO1, gene expression analysis, FoxO1 binding site analysis in promoters of PGC-1α/CREB/GR, HCV infection model","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct deacetylation of FoxO1 demonstrated plus downstream gene expression, single lab, multiple targets examined","pmids":["28733598"],"is_preprint":false},{"year":2018,"finding":"HDAC9 forms a ternary complex with the chromatin-remodeling enzyme BRG1 and the lncRNA MALAT1. This HDAC9-MALAT1-BRG1 complex binds chromatin and represses contractile protein gene expression in vascular smooth muscle cells (VSMCs) in association with gain of histone H3-lysine 27 trimethylation. Disruption of Malat1 or Hdac9 restores contractile protein expression, improves aortic mural architecture, and inhibits experimental aneurysm growth.","method":"Co-immunoprecipitation of ternary complex, ChIP assay (H3K27me3), loss-of-function (Malat1 or Hdac9 disruption), in vivo aneurysm model","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Moderate — Co-IP of ternary complex plus ChIP plus in vivo loss-of-function with structural phenotype, multiple orthogonal methods","pmids":["29520069"],"is_preprint":false},{"year":2019,"finding":"Increased expression of HDAC9 in human aortic smooth muscle cells promotes calcification and reduces contractility; inhibition of HDAC9 inhibits calcification and enhances cell contractility. HDAC9-knockout mice show 40% reduction in aortic calcification and improved survival in a vascular calcification model.","method":"HDAC9 gain- and loss-of-function in human aortic smooth muscle cells, HDAC9 knockout mice in matrix Gla protein-deficient background, calcification assays","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — complementary gain- and loss-of-function in human cells plus in vivo KO model with quantitative phenotype","pmids":["31659325"],"is_preprint":false},{"year":2018,"finding":"HDAC9 promotes brain ischemic injury by activating IκBα/NF-κB and MAPK signaling pathways. HDAC9 knockout reduces infarct volume, improves neurological function, and suppresses expression of iNOS, COX-2, IL-1β, IL-6, TNF-α, and IL-18 in ischemia/reperfusion injury. In vitro, HDAC9 inhibition-reduced inflammation through the IκBα/NF-κB pathway is reversed by promoting MAPK activity, placing HDAC9 upstream of both pathways.","method":"HDAC9 knockout mice, ischemia/reperfusion model, western blot for phosphorylated NF-κB/IκBα/MAPKs, LPS-stimulated cell model with pathway rescue","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO with defined inflammatory phenotype plus epistasis via MAPK rescue, single lab","pmids":["30031609"],"is_preprint":false},{"year":2019,"finding":"HDAC9 knockdown inhibits cell growth, reduces colony formation, and induces apoptosis and cell cycle arrest in gastric cancer cells, and suppresses tumor growth in vivo. HDAC9 siRNA enhanced antitumor efficacy of cisplatin in gastric cancer.","method":"HDAC9 siRNA knockdown, in vitro proliferation/apoptosis/cell cycle assays, in vivo xenograft model","journal":"Experimental & molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean KD with defined cellular phenotype in vitro and in vivo, single lab","pmids":["31451695"],"is_preprint":false},{"year":2016,"finding":"HDAC9 deregulated expression in B cells (Eμ-HDAC9 transgenic mice) promotes development of splenic marginal zone lymphoma and lymphoproliferative disease progressing to DLBCL. HDAC9 appears to contribute to lymphomagenesis by modulating BCL6 activity and p53 tumor suppressor function.","method":"Eμ-HDAC9 transgenic mouse model, gene expression profiling, analysis of BCL6 and p53 pathways","journal":"Disease models & mechanisms","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — transgenic mouse with defined lymphoma phenotype and pathway analysis, single lab","pmids":["27799148"],"is_preprint":false},{"year":2019,"finding":"In MCF7 breast cancer cells, HDAC9 overexpression decreased ERα mRNA and protein expression and inhibited ERα transcriptional activity. HDAC9-overexpressing cells were less sensitive to tamoxifen antiproliferative effects, demonstrating a mechanistic role for HDAC9 in antiestrogen resistance through suppression of ERα signaling.","method":"HDAC9 overexpression in MCF7 cells, transcriptomic analysis, ERα expression and activity assays, antiproliferative assay","journal":"Molecular oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain-of-function with mechanistic ERα pathway analysis plus functional drug response assay, single lab","pmids":["31099456"],"is_preprint":false},{"year":2019,"finding":"HDAC9 dysregulation in trophoblast cells promotes cell migration and invasion by repressing TIMP3 expression through promoter histone hypoacetylation. HDAC9 knockdown in HTR-8/SVneo cells inhibited migration and invasion, and was associated with upregulation of TIMP3 due to histone hyperacetylation at the TIMP3 promoter detected by ChIP-qPCR.","method":"HDAC9 knockdown, transwell migration/invasion assays, ChIP-qPCR of TIMP3 promoter histone acetylation","journal":"American journal of hypertension","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — knockdown plus ChIP-qPCR demonstrating direct promoter regulation, single lab","pmids":["30715128"],"is_preprint":false},{"year":2021,"finding":"IL-4 inhibits regulatory T cell differentiation and Foxp3 expression through a STAT6-dependent mechanism involving HDAC9-mediated histone deacetylation at the Foxp3 locus, decreasing chromatin accessibility and Foxp3 gene transcription.","method":"HDAC9 involvement assay, STAT6-dependence experiments, chromatin accessibility assay, pan-HDAC inhibitor rescue, mouse model of allergic airway inflammation","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mechanistic pathway placement with STAT6 dependence plus functional rescue with HDAC inhibitor, single lab","pmids":["34006836"],"is_preprint":false},{"year":2022,"finding":"β-hydroxybutyrate (BHB) downregulates HDAC9 expression and suppresses vascular calcification. HDAC9 promotes VSMC calcification via activation of the NF-κB signaling pathway; inhibition of NF-κB attenuated HDAC9-induced VSMC calcification. Both pharmacological inhibition and knockdown of HDAC9 attenuated calcification, while HDAC9 overexpression exacerbated it.","method":"RNA-seq, RT-qPCR, western blot, HDAC9 knockdown/overexpression, NF-κB inhibition rescue, calcification assays in VSMCs and aortic rings, in vivo CKD rat and mouse models","journal":"The Journal of pathology","confidence":"High","confidence_rationale":"Tier 2 / Strong — complementary gain- and loss-of-function plus NF-κB epistasis rescue plus in vivo models, multiple orthogonal methods","pmids":["35894849"],"is_preprint":false},{"year":2020,"finding":"HDAC9 regulates autophagy in bone marrow mesenchymal stem cells (BMMSCs) by controlling H3K9 acetylation at the promoters of autophagic genes ATG7, BECN1, and LC3a/b, thereby affecting lineage differentiation. Elevated HDAC9 in aged mice impairs autophagy and shifts BMMSCs toward adipogenesis; HDAC9 inhibition restored lineage differentiation and improved bone mass.","method":"Western blot, ChIP assay (H3K9ac at autophagic gene promoters), TEM/confocal microscopy, micro-CT, HDAC9 inhibitor treatment","journal":"Stem cell research & therapy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP assay demonstrating direct promoter regulation plus functional differentiation and in vivo bone phenotype, single lab","pmids":["32620134"],"is_preprint":false},{"year":2015,"finding":"HDAC9 knockdown in retinoblastoma cells induces cell cycle arrest at G1 phase with significant decrease in cyclin E2 and CDK2 expression, inhibits proliferation in vitro, and inhibits tumor growth in vivo.","method":"HDAC9 knockdown, cell cycle analysis (flow cytometry), western blot for cyclin E2/CDK2, xenograft tumor model","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean KD with defined cell cycle arrest phenotype and mechanistic downstream targets identified, single lab","pmids":["27033599"],"is_preprint":false},{"year":2015,"finding":"HDAC9 epigenetically represses p53 transcription in osteosarcoma cells by binding to the p53 proximal promoter region, as demonstrated by ChIP assay. HDAC9 overexpression promoted cell proliferation and invasion.","method":"ChIP assay (HDAC9 binding to p53 promoter), HDAC9 overexpression, proliferation and invasion assays","journal":"International journal of clinical and experimental medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP assay demonstrating direct promoter binding plus functional overexpression phenotype, single lab","pmids":["26380023"],"is_preprint":false}],"current_model":"HDAC9 is a class IIa histone deacetylase that shuttles between nucleus and cytoplasm, represses MEF2-dependent transcription through direct MEF2 binding and recruitment of corepressors (CtBP, HDAC1, SMRT/NCoR), is regulated by phosphorylation-dependent 14-3-3 binding that exports it from the nucleus, deacetylates non-histone substrates including FoxO1 to regulate gluconeogenesis, forms a ternary repressive complex with BRG1 and MALAT1 lncRNA to silence contractile genes in vascular smooth muscle cells, promotes vascular calcification via NF-κB activation, controls bone remodeling by suppressing osteoclastogenesis through a PPARγ/RANKL loop, regulates T regulatory cell function by modulating Foxp3 locus histone acetylation, and controls autophagic gene expression via H3K9 acetylation at promoters of ATG7, BECN1, and LC3a/b."},"narrative":{"mechanistic_narrative":"HDAC9 is a class IIa histone deacetylase that functions as a signal-responsive transcriptional repressor, controlling differentiation programs in muscle, immune, skeletal, and vascular lineages through both catalytic deacetylation and corepressor scaffolding [PMID:11535832, PMID:11390982]. Its founding activity is repression of MEF2-dependent transcription: HDAC9 and its catalytically inactive splice isoform MITR bind directly to the MADS/MEF2 domain of MEF2 proteins and recruit corepressors including HDAC1 and CtBP through a conserved P-X-D-L-R motif, with CtBP-dependent and -independent repression operating in parallel [PMID:11535832, PMID:10487760, PMID:11022042]. This repression is switched off by phosphorylation of Ser-218 and Ser-448, which promotes 14-3-3 binding, disrupts the MEF2 interaction, alters nuclear distribution, and relieves silencing of muscle-specific genes [PMID:11390982]. Beyond histone substrates, HDAC9 deacetylates the transcription factor FoxO1 to drive hepatic gluconeogenic gene expression (PGC-1α, CREB, GR) [PMID:28733598], and it acts at chromatin through targeted histone deacetylation—repressing TIMP3 and the Foxp3 locus, and controlling H3K9 acetylation at autophagy gene promoters (ATG7, BECN1, LC3a/b) to govern lineage differentiation [PMID:30715128, PMID:34006836, PMID:32620134]. In vascular smooth muscle cells HDAC9 assembles a ternary repressive complex with the chromatin remodeler BRG1 and the lncRNA MALAT1 to silence contractile genes and, via NF-κB activation, promotes vascular calcification, driving aneurysm and calcification pathology in vivo [PMID:29520069, PMID:31659325, PMID:35894849]. HDAC9 also restrains osteoclastogenesis and adipogenesis through a mutually suppressive loop with PPARγ/RANKL signaling in concert with SMRT/NCoR corepressors [PMID:25793404, PMID:21247904]. Across multiple cancers HDAC9 acts as a pro-tumorigenic regulator, repressing p53 and ERα and supporting proliferation and survival [PMID:31451695, PMID:31099456, PMID:26380023].","teleology":[{"year":1999,"claim":"Established that an HDAC9 isoform represses MEF2-dependent transcription by directly engaging MEF2 and recruiting deacetylase machinery, defining HDAC9 as a MEF2 corepressor.","evidence":"Yeast two-hybrid, direct binding and transcription assays in Xenopus embryos (MITR–MEF2D/A binding, HDAC1 recruitment)","pmids":["10487760"],"confidence":"High","gaps":["Did not establish the catalytic contribution of full-length HDAC9","Physiological gene targets of MEF2 repression not defined"]},{"year":2001,"claim":"Defined HDAC9 as a catalytically active deacetylase with multiple isoforms (including catalytic-domain-lacking MITR) and confirmed MEF2 repression, while delineating CtBP-dependent and -independent repression routes.","evidence":"Cloning, in vitro deacetylase assays, CtBP-motif mutagenesis, Co-IP, reporter assays","pmids":["11535832","11022042"],"confidence":"High","gaps":["Endogenous histone substrates not mapped","Relative contributions of catalytic vs scaffolding repression unresolved"]},{"year":2001,"claim":"Identified the phosphorylation/14-3-3 switch that converts HDAC9/MITR from repressor to permissive state, explaining how external signals release MEF2-dependent muscle genes.","evidence":"Site-directed mutagenesis of Ser-218/Ser-448, Co-IP, immunofluorescence, myogenic differentiation assays","pmids":["11390982"],"confidence":"High","gaps":["Kinases phosphorylating these serines not identified in this work","Mechanism of nuclear redistribution not structurally resolved"]},{"year":2009,"claim":"Linked HDAC9 to regulatory T cell suppressive function via HSP70 and Foxp3, extending its repressor role into immune tolerance.","evidence":"HDAC9 knockout mice, Treg transfer, HSP70–Foxp3 Co-IP, HSP70 inhibition/overexpression, colitis model","pmids":["19879272"],"confidence":"High","gaps":["Direct deacetylation target in this axis not defined","Whether effect is catalytic or scaffolding unclear"]},{"year":2011,"claim":"Showed HDAC9/MITR directs mesenchymal lineage choice toward osteogenesis by directly antagonizing PPARγ-2 transcriptional activity.","evidence":"EZH2 ChIP-on-chip, differentiation assays, PPARγ-2 interaction studies","pmids":["21247904"],"confidence":"Medium","gaps":["Interaction not validated by reciprocal Co-IP","Single lab"]},{"year":2015,"claim":"Established HDAC9 as a suppressor of osteoclastogenesis through a mutual PPARγ/RANKL feedback loop acting with SMRT/NCoR, demonstrated to be hematopoietic-intrinsic.","evidence":"HDAC9 KO mice, bone marrow transplantation, ex vivo osteoclast differentiation, corepressor interaction assays","pmids":["25793404"],"confidence":"High","gaps":["Direct chromatin targets in osteoclast precursors not mapped"]},{"year":2015,"claim":"Extended HDAC9 corepressor activity to neuromuscular plasticity, showing collaboration with Dach2 to suppress reinnervation genes Myog and Gdf5.","evidence":"Loss-of-function in mouse skeletal muscle, gene expression and epistasis analysis","pmids":["26483211"],"confidence":"Medium","gaps":["Direct vs indirect regulation of Myog/Gdf5 promoters not resolved","Molecular nature of Dach2–HDAC9 cooperation undefined"]},{"year":2015,"claim":"Implicated HDAC9 as pro-tumorigenic in multiple contexts—upstream of TAZ in glioblastoma, repressing p53 at its promoter in osteosarcoma, and driving retinoblastoma cell cycle progression.","evidence":"Knockdown/overexpression, rescue epistasis, ChIP of p53 promoter, cell cycle/xenograft assays","pmids":["25760078","26380023","27033599"],"confidence":"Medium","gaps":["Direct vs indirect TAZ regulation unclear","Each finding single lab and tumor-type specific"]},{"year":2016,"claim":"Demonstrated that HDAC9 overexpression in B cells drives lymphomagenesis through BCL6 and p53 pathway modulation.","evidence":"Eμ-HDAC9 transgenic mice, gene expression profiling, BCL6/p53 pathway analysis","pmids":["27799148"],"confidence":"Medium","gaps":["Direct molecular targets of HDAC9 in B cells not defined","Catalytic requirement not tested"]},{"year":2017,"claim":"Identified a non-histone substrate by showing HDAC9 deacetylates FoxO1 to amplify hepatic gluconeogenic gene programs, a pathway co-opted during HCV infection.","evidence":"FoxO1 deacetylation assay, gene expression of PGC-1α/CREB/GR, FoxO1 promoter binding analysis, HCV model","pmids":["28733598"],"confidence":"Medium","gaps":["Direct deacetylation residues not mapped","Single lab"]},{"year":2018,"claim":"Defined a ternary HDAC9–BRG1–MALAT1 chromatin complex that silences VSMC contractile genes with H3K27me3 gain, linking HDAC9 to aneurysm pathology.","evidence":"Co-IP of ternary complex, ChIP for H3K27me3, Malat1/Hdac9 loss-of-function, in vivo aneurysm model","pmids":["29520069"],"confidence":"High","gaps":["Stoichiometry and assembly order of the complex unresolved","Whether HDAC9 catalytic activity is required not isolated"]},{"year":2018,"claim":"Placed HDAC9 upstream of both IκBα/NF-κB and MAPK signaling in driving ischemic brain inflammatory injury.","evidence":"HDAC9 KO mice, ischemia/reperfusion model, phospho-protein western blots, LPS cell model with MAPK rescue","pmids":["30031609"],"confidence":"Medium","gaps":["Direct molecular link between HDAC9 and these signaling nodes undefined","Single lab"]},{"year":2019,"claim":"Established HDAC9 as a driver of vascular calcification with reduced contractility, confirmed by complementary gain/loss-of-function and in vivo KO.","evidence":"Gain/loss-of-function in human aortic SMCs, HDAC9 KO in MGP-deficient mice, calcification assays","pmids":["31659325"],"confidence":"High","gaps":["Mechanistic chromatin targets in calcifying SMCs not detailed in this study"]},{"year":2019,"claim":"Extended HDAC9's promoter-level repression to trophoblast invasion (TIMP3) and antiestrogen resistance (ERα) and to gastric cancer growth and chemosensitivity.","evidence":"Knockdown/overexpression, ChIP-qPCR of TIMP3 promoter acetylation, ERα activity assays, gastric xenografts with cisplatin","pmids":["30715128","31099456","31451695"],"confidence":"Medium","gaps":["ERα regulation mechanism (direct vs indirect) not fully resolved","Each context single lab"]},{"year":2020,"claim":"Showed HDAC9 controls autophagy gene expression via H3K9 deacetylation at ATG7, BECN1, and LC3a/b promoters, coupling its activity to age-related skeletal stem cell lineage shifts.","evidence":"ChIP for H3K9ac at autophagic gene promoters, TEM/confocal, micro-CT, HDAC9 inhibitor treatment in aged mice","pmids":["32620134"],"confidence":"Medium","gaps":["Direct binding of HDAC9 to these promoters vs indirect effect not fully separated","Single lab"]},{"year":2021,"claim":"Positioned HDAC9 downstream of IL-4/STAT6 in deacetylating the Foxp3 locus to limit chromatin accessibility and regulatory T cell differentiation.","evidence":"STAT6-dependence experiments, chromatin accessibility assays, pan-HDAC inhibitor rescue, allergic airway model","pmids":["34006836"],"confidence":"Medium","gaps":["Pan-HDAC inhibitor not HDAC9-specific","Direct recruitment mechanism to Foxp3 locus undefined"]},{"year":2022,"claim":"Confirmed NF-κB activation as the effector pathway for HDAC9-driven VSMC calcification and identified β-hydroxybutyrate as a suppressor of HDAC9 expression.","evidence":"RNA-seq, gain/loss-of-function, NF-κB inhibition rescue, calcification assays, CKD rat/mouse models","pmids":["35894849"],"confidence":"High","gaps":["Mechanism by which HDAC9 activates NF-κB not molecularly defined","Direct chromatin targets in this axis unmapped"]},{"year":null,"claim":"Whether HDAC9's many context-specific phenotypes depend on catalytic deacetylation versus corepressor scaffolding, and the direct genomic and non-histone substrate repertoire in each tissue, remain unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No catalytic-dead vs scaffolding-only structure-function dissection across tissues","Genome-wide direct HDAC9 binding map absent","Non-histone substrate spectrum beyond FoxO1 uncharacterized"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,9]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[1,2,10,21]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[0]},{"term_id":"GO:0042393","term_label":"histone binding","supporting_discovery_ids":[16,19]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[3,7]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[3]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,1,10]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[10,16,19]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[3,6,7]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[4,17]},{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[19]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[5,12,18]}],"complexes":["HDAC9-MALAT1-BRG1 ternary repressive complex"],"partners":["MEF2D","MEF2A","HDAC1","CTBP","YWHA(14-3-3)","PPARG","BRG1","FOXO1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9UKV0","full_name":"Histone deacetylase 9","aliases":["Histone deacetylase 7B","HD7","HD7b","Histone deacetylase-related protein","MEF2-interacting transcription repressor MITR"],"length_aa":1011,"mass_kda":111.3,"function":"Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4). Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Represses MEF2-dependent transcription Isoform 3 lacks active site residues and therefore is catalytically inactive. Represses MEF2-dependent transcription by recruiting HDAC1 and/or HDAC3. Seems to inhibit skeletal myogenesis and to be involved in heart development. Protects neurons from apoptosis, both by inhibiting JUN phosphorylation by MAPK10 and by repressing JUN transcription via HDAC1 recruitment to JUN promoter","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q9UKV0/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/HDAC9","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/HDAC9","total_profiled":1310},"omim":[{"mim_id":"620457","title":"AURICULOCONDYLAR SYNDROME 4; ARCND4","url":"https://www.omim.org/entry/620457"},{"mim_id":"616096","title":"MYOSIN HEAVY CHAIN-ASSOCIATED RNA TRANSCRIPT, NONCODING; MHRT","url":"https://www.omim.org/entry/616096"},{"mim_id":"612547","title":"TRANSMEMBRANE PROTEIN 270; TMEM270","url":"https://www.omim.org/entry/612547"},{"mim_id":"606543","title":"HISTONE DEACETYLASE 9; HDAC9","url":"https://www.omim.org/entry/606543"},{"mim_id":"602483","title":"AURICULOCONDYLAR SYNDROME 1; ARCND1","url":"https://www.omim.org/entry/602483"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoplasm","reliability":"Approved"},{"location":"Mitotic chromosome","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/HDAC9"},"hgnc":{"alias_symbol":["KIAA0744","HDAC","MITR","HD7","HDAC7B"],"prev_symbol":[]},"alphafold":{"accession":"Q9UKV0","domains":[{"cath_id":"3.40.800.20","chopping":"634-1007","consensus_level":"high","plddt":94.0888,"start":634,"end":1007}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9UKV0","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9UKV0-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9UKV0-F1-predicted_aligned_error_v6.png","plddt_mean":64.25},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=HDAC9","jax_strain_url":"https://www.jax.org/strain/search?query=HDAC9"},"sequence":{"accession":"Q9UKV0","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9UKV0.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9UKV0/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9UKV0"}},"corpus_meta":[{"pmid":"24382387","id":"PMC_24382387","title":"New and emerging HDAC inhibitors for cancer treatment.","date":"2014","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/24382387","citation_count":1126,"is_preprint":false},{"pmid":"27599530","id":"PMC_27599530","title":"HDACs and HDAC Inhibitors in Cancer Development and Therapy.","date":"2016","source":"Cold Spring Harbor perspectives in medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27599530","citation_count":1040,"is_preprint":false},{"pmid":"19775759","id":"PMC_19775759","title":"Multiple roles of HDAC inhibition in neurodegenerative conditions.","date":"2009","source":"Trends in neurosciences","url":"https://pubmed.ncbi.nlm.nih.gov/19775759","citation_count":532,"is_preprint":false},{"pmid":"18206423","id":"PMC_18206423","title":"Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders.","date":"2008","source":"Current opinion in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/18206423","citation_count":359,"is_preprint":false},{"pmid":"26865995","id":"PMC_26865995","title":"HDAC and HDAC Inhibitor: From Cancer to Cardiovascular Diseases.","date":"2016","source":"Chonnam medical journal","url":"https://pubmed.ncbi.nlm.nih.gov/26865995","citation_count":353,"is_preprint":false},{"pmid":"20980063","id":"PMC_20980063","title":"Targeting the correct HDAC(s) to treat cognitive disorders.","date":"2010","source":"Trends in pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/20980063","citation_count":300,"is_preprint":false},{"pmid":"29551127","id":"PMC_29551127","title":"Advances and Challenges of HDAC Inhibitors in Cancer Therapeutics.","date":"2018","source":"Advances in cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/29551127","citation_count":277,"is_preprint":false},{"pmid":"33872660","id":"PMC_33872660","title":"Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy.","date":"2021","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33872660","citation_count":274,"is_preprint":false},{"pmid":"23141799","id":"PMC_23141799","title":"HDAC inhibitor-based therapies: can we interpret the code?","date":"2012","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/23141799","citation_count":271,"is_preprint":false},{"pmid":"11535832","id":"PMC_11535832","title":"Cloning and characterization of a histone deacetylase, HDAC9.","date":"2001","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/11535832","citation_count":210,"is_preprint":false},{"pmid":"19359091","id":"PMC_19359091","title":"Enhancing the apoptotic and therapeutic effects of HDAC inhibitors.","date":"2009","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/19359091","citation_count":204,"is_preprint":false},{"pmid":"19879272","id":"PMC_19879272","title":"Inhibition of HDAC9 increases T regulatory cell function and prevents colitis in mice.","date":"2009","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/19879272","citation_count":203,"is_preprint":false},{"pmid":"21274504","id":"PMC_21274504","title":"Histone deacetylase (HDAC) inhibition as a novel treatment for diabetes mellitus.","date":"2011","source":"Molecular medicine (Cambridge, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/21274504","citation_count":198,"is_preprint":false},{"pmid":"18326939","id":"PMC_18326939","title":"HDACs and HDAC inhibitors in colon cancer.","date":"2008","source":"Epigenetics","url":"https://pubmed.ncbi.nlm.nih.gov/18326939","citation_count":187,"is_preprint":false},{"pmid":"11022042","id":"PMC_11022042","title":"Association of COOH-terminal-binding protein (CtBP) and MEF2-interacting transcription repressor (MITR) contributes to transcriptional repression of the MEF2 transcription factor.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11022042","citation_count":185,"is_preprint":false},{"pmid":"10487760","id":"PMC_10487760","title":"MEF-2 function is modified by a novel co-repressor, MITR.","date":"1999","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/10487760","citation_count":171,"is_preprint":false},{"pmid":"31739588","id":"PMC_31739588","title":"HDAC Inhibitors in Acute Myeloid Leukemia.","date":"2019","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/31739588","citation_count":158,"is_preprint":false},{"pmid":"30649740","id":"PMC_30649740","title":"Safety and Tolerability of Histone Deacetylase (HDAC) Inhibitors in Oncology.","date":"2019","source":"Drug safety","url":"https://pubmed.ncbi.nlm.nih.gov/30649740","citation_count":153,"is_preprint":false},{"pmid":"25115382","id":"PMC_25115382","title":"HDAC inhibitors and immunotherapy; a double edged sword?","date":"2014","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/25115382","citation_count":145,"is_preprint":false},{"pmid":"16267097","id":"PMC_16267097","title":"Dietary HDAC inhibitors: time to rethink weak ligands in cancer chemoprevention?","date":"2005","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/16267097","citation_count":139,"is_preprint":false},{"pmid":"27371876","id":"PMC_27371876","title":"Histone deacetylase 3 (HDAC 3) as emerging drug target in NF-κB-mediated inflammation.","date":"2016","source":"Current opinion in chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/27371876","citation_count":130,"is_preprint":false},{"pmid":"31659325","id":"PMC_31659325","title":"HDAC9 is implicated in atherosclerotic aortic calcification and affects vascular smooth muscle cell phenotype.","date":"2019","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/31659325","citation_count":122,"is_preprint":false},{"pmid":"29520069","id":"PMC_29520069","title":"An HDAC9-MALAT1-BRG1 complex mediates smooth muscle dysfunction in thoracic aortic aneurysm.","date":"2018","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/29520069","citation_count":122,"is_preprint":false},{"pmid":"19515748","id":"PMC_19515748","title":"HDAC inhibitor-based therapies and haematological malignancy.","date":"2009","source":"Annals of oncology : official journal of the European Society for Medical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/19515748","citation_count":119,"is_preprint":false},{"pmid":"20123018","id":"PMC_20123018","title":"HDAC inhibitors and neurodegeneration: at the edge between protection and damage.","date":"2010","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/20123018","citation_count":115,"is_preprint":false},{"pmid":"25972179","id":"PMC_25972179","title":"ApoE4 and Aβ Oligomers Reduce BDNF Expression via HDAC Nuclear Translocation.","date":"2015","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/25972179","citation_count":113,"is_preprint":false},{"pmid":"23088869","id":"PMC_23088869","title":"HDAC inhibitors: roles of DNA damage and repair.","date":"2012","source":"Advances in cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/23088869","citation_count":112,"is_preprint":false},{"pmid":"25782916","id":"PMC_25782916","title":"HDAC Inhibitors as Novel Anti-Cancer Therapeutics.","date":"2015","source":"Recent patents on anti-cancer drug discovery","url":"https://pubmed.ncbi.nlm.nih.gov/25782916","citation_count":108,"is_preprint":false},{"pmid":"24727244","id":"PMC_24727244","title":"HDAC signaling in neuronal development and axon regeneration.","date":"2014","source":"Current opinion in neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/24727244","citation_count":108,"is_preprint":false},{"pmid":"16153738","id":"PMC_16153738","title":"Genome-wide analysis of HDAC function.","date":"2005","source":"Trends in genetics : TIG","url":"https://pubmed.ncbi.nlm.nih.gov/16153738","citation_count":99,"is_preprint":false},{"pmid":"35484434","id":"PMC_35484434","title":"Target deconvolution of HDAC pharmacopoeia reveals MBLAC2 as common off-target.","date":"2022","source":"Nature chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/35484434","citation_count":99,"is_preprint":false},{"pmid":"27112360","id":"PMC_27112360","title":"How do tumor cells respond to HDAC inhibition?","date":"2016","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/27112360","citation_count":94,"is_preprint":false},{"pmid":"11390982","id":"PMC_11390982","title":"The transcriptional corepressor MITR is a signal-responsive inhibitor of myogenesis.","date":"2001","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/11390982","citation_count":93,"is_preprint":false},{"pmid":"22683268","id":"PMC_22683268","title":"Expression noise and acetylation profiles distinguish HDAC functions.","date":"2012","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/22683268","citation_count":91,"is_preprint":false},{"pmid":"23499301","id":"PMC_23499301","title":"HDAC-dependent ventricular remodeling.","date":"2013","source":"Trends in cardiovascular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/23499301","citation_count":90,"is_preprint":false},{"pmid":"21879444","id":"PMC_21879444","title":"The biology of HDAC in cancer: the nuclear and epigenetic components.","date":"2011","source":"Handbook of experimental pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/21879444","citation_count":87,"is_preprint":false},{"pmid":"33077264","id":"PMC_33077264","title":"Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.","date":"2020","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/33077264","citation_count":84,"is_preprint":false},{"pmid":"16978537","id":"PMC_16978537","title":"The molecular mechanism of HDAC inhibitors in anticancer effects.","date":"2006","source":"Cellular & molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16978537","citation_count":78,"is_preprint":false},{"pmid":"24732587","id":"PMC_24732587","title":"Vascular histone deacetylation by pharmacological HDAC inhibition.","date":"2014","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/24732587","citation_count":73,"is_preprint":false},{"pmid":"33015069","id":"PMC_33015069","title":"Recent Update of HDAC Inhibitors in Lymphoma.","date":"2020","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/33015069","citation_count":72,"is_preprint":false},{"pmid":"36036883","id":"PMC_36036883","title":"HDAC6: A unique HDAC family member as a cancer target.","date":"2022","source":"Cellular oncology (Dordrecht, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/36036883","citation_count":71,"is_preprint":false},{"pmid":"21298214","id":"PMC_21298214","title":"HDAC inhibition and graft versus host disease.","date":"2011","source":"Molecular medicine (Cambridge, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/21298214","citation_count":68,"is_preprint":false},{"pmid":"25760078","id":"PMC_25760078","title":"HDAC9 promotes glioblastoma growth via TAZ-mediated EGFR pathway activation.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/25760078","citation_count":65,"is_preprint":false},{"pmid":"30979734","id":"PMC_30979734","title":"Precision Targeting with EZH2 and HDAC Inhibitors in Epigenetically Dysregulated Lymphomas.","date":"2019","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/30979734","citation_count":62,"is_preprint":false},{"pmid":"30674261","id":"PMC_30674261","title":"Zinc-dependent Deacetylase (HDAC) Inhibitors with Different Zinc Binding Groups.","date":"2019","source":"Current topics in medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30674261","citation_count":61,"is_preprint":false},{"pmid":"35163980","id":"PMC_35163980","title":"HDAC Inhibitors: Innovative Strategies for Their Design and Applications.","date":"2022","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/35163980","citation_count":60,"is_preprint":false},{"pmid":"22460138","id":"PMC_22460138","title":"HDAC inhibitor therapy in autoimmunity and transplantation.","date":"2012","source":"Annals of the rheumatic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/22460138","citation_count":59,"is_preprint":false},{"pmid":"20585871","id":"PMC_20585871","title":"Histone deacetylase (HDAC) 1 and 2 expression and chemotherapy in gastric cancer.","date":"2010","source":"Annals of surgical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/20585871","citation_count":58,"is_preprint":false},{"pmid":"34438016","id":"PMC_34438016","title":"Backstage players of fibrosis: NOX4, mTOR, HDAC, and S1P; companions of TGF-β.","date":"2021","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/34438016","citation_count":57,"is_preprint":false},{"pmid":"25793404","id":"PMC_25793404","title":"HDAC9 Inhibits Osteoclastogenesis via Mutual Suppression of PPARγ/RANKL Signaling.","date":"2015","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/25793404","citation_count":56,"is_preprint":false},{"pmid":"22032556","id":"PMC_22032556","title":"Susceptibility variants on chromosome 7p21.1 suggest HDAC9 as a new candidate gene for male-pattern baldness.","date":"2011","source":"The British journal of dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/22032556","citation_count":54,"is_preprint":false},{"pmid":"37214715","id":"PMC_37214715","title":"Single Inhibitors versus Dual Inhibitors: Role of HDAC in Cancer.","date":"2023","source":"ACS omega","url":"https://pubmed.ncbi.nlm.nih.gov/37214715","citation_count":52,"is_preprint":false},{"pmid":"32703113","id":"PMC_32703113","title":"HDAC inhibition reduces white matter injury after intracerebral hemorrhage.","date":"2020","source":"Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/32703113","citation_count":50,"is_preprint":false},{"pmid":"21141730","id":"PMC_21141730","title":"HDAC inhibitors and cancer therapy.","date":"2011","source":"Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques","url":"https://pubmed.ncbi.nlm.nih.gov/21141730","citation_count":50,"is_preprint":false},{"pmid":"21247904","id":"PMC_21247904","title":"Myocyte enhancer factor-2 interacting transcriptional repressor (MITR) is a switch that promotes osteogenesis and inhibits adipogenesis of mesenchymal stem cells by inactivating peroxisome proliferator-activated receptor gamma-2.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21247904","citation_count":50,"is_preprint":false},{"pmid":"33189849","id":"PMC_33189849","title":"Anticancer properties of chimeric HDAC and kinase inhibitors.","date":"2020","source":"Seminars in cancer biology","url":"https://pubmed.ncbi.nlm.nih.gov/33189849","citation_count":49,"is_preprint":false},{"pmid":"28827187","id":"PMC_28827187","title":"Epigenetics in osteoarthritis: Potential of HDAC inhibitors as therapeutics.","date":"2017","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/28827187","citation_count":49,"is_preprint":false},{"pmid":"36096240","id":"PMC_36096240","title":"Current trends in development of HDAC-based chemotherapeutics.","date":"2022","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36096240","citation_count":48,"is_preprint":false},{"pmid":"34822450","id":"PMC_34822450","title":"Metabolism, HDACs, and HDAC Inhibitors: A Systems Biology Perspective.","date":"2021","source":"Metabolites","url":"https://pubmed.ncbi.nlm.nih.gov/34822450","citation_count":47,"is_preprint":false},{"pmid":"22077150","id":"PMC_22077150","title":"Hdac-mediated control of endochondral and intramembranous ossification.","date":"2011","source":"Critical reviews in eukaryotic gene expression","url":"https://pubmed.ncbi.nlm.nih.gov/22077150","citation_count":47,"is_preprint":false},{"pmid":"29233541","id":"PMC_29233541","title":"Combination Therapies Targeting HDAC and IKK in Solid Tumors.","date":"2017","source":"Trends in pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/29233541","citation_count":46,"is_preprint":false},{"pmid":"28687272","id":"PMC_28687272","title":"Interstrand Crosslink Repair as a Target for HDAC Inhibition.","date":"2017","source":"Trends in pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/28687272","citation_count":46,"is_preprint":false},{"pmid":"21327298","id":"PMC_21327298","title":"HDAC inhibition in lupus models.","date":"2011","source":"Molecular medicine (Cambridge, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/21327298","citation_count":45,"is_preprint":false},{"pmid":"35894849","id":"PMC_35894849","title":"Downregulation of HDAC9 by the ketone metabolite β-hydroxybutyrate suppresses vascular calcification.","date":"2022","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/35894849","citation_count":45,"is_preprint":false},{"pmid":"27799148","id":"PMC_27799148","title":"Deregulated expression of HDAC9 in B cells promotes development of lymphoproliferative disease and lymphoma in mice.","date":"2016","source":"Disease models & mechanisms","url":"https://pubmed.ncbi.nlm.nih.gov/27799148","citation_count":43,"is_preprint":false},{"pmid":"27913271","id":"PMC_27913271","title":"Histone deacetylases (HDAC) in physiological and pathological bone remodelling.","date":"2016","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/27913271","citation_count":42,"is_preprint":false},{"pmid":"34968229","id":"PMC_34968229","title":"Targeting HDAC Complexes in Asthma and COPD.","date":"2019","source":"Epigenomes","url":"https://pubmed.ncbi.nlm.nih.gov/34968229","citation_count":42,"is_preprint":false},{"pmid":"24556916","id":"PMC_24556916","title":"Pazopanib and HDAC inhibitors interact to kill sarcoma cells.","date":"2014","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/24556916","citation_count":42,"is_preprint":false},{"pmid":"34318404","id":"PMC_34318404","title":"Histone deacetylase (HDAC) 9: versatile biological functions and emerging roles in human cancer.","date":"2021","source":"Cellular oncology (Dordrecht, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/34318404","citation_count":41,"is_preprint":false},{"pmid":"32987782","id":"PMC_32987782","title":"Bifunctional HDAC Therapeutics: One Drug to Rule Them All?","date":"2020","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/32987782","citation_count":41,"is_preprint":false},{"pmid":"31451695","id":"PMC_31451695","title":"Identification of HDAC9 as a viable therapeutic target for the treatment of gastric cancer.","date":"2019","source":"Experimental & molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31451695","citation_count":41,"is_preprint":false},{"pmid":"23088873","id":"PMC_23088873","title":"HDAC inhibitors and chaperone function.","date":"2012","source":"Advances in cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/23088873","citation_count":38,"is_preprint":false},{"pmid":"30031609","id":"PMC_30031609","title":"HDAC9 promotes brain ischemic injury by provoking IκBα/NF-κB and MAPKs signaling pathways.","date":"2018","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/30031609","citation_count":38,"is_preprint":false},{"pmid":"31477543","id":"PMC_31477543","title":"Role of HDAC inhibitors in diabetes mellitus.","date":"2019","source":"Current research in translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31477543","citation_count":37,"is_preprint":false},{"pmid":"27033599","id":"PMC_27033599","title":"Downregulation of HDAC9 inhibits cell proliferation and tumor formation by inducing cell cycle arrest in retinoblastoma.","date":"2016","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/27033599","citation_count":35,"is_preprint":false},{"pmid":"31099456","id":"PMC_31099456","title":"Increased expression of the HDAC9 gene is associated with antiestrogen resistance of breast cancers.","date":"2019","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/31099456","citation_count":34,"is_preprint":false},{"pmid":"28447074","id":"PMC_28447074","title":"Chidamide tablets: HDAC inhibition to treat lymphoma.","date":"2017","source":"Drugs of today (Barcelona, Spain : 1998)","url":"https://pubmed.ncbi.nlm.nih.gov/28447074","citation_count":34,"is_preprint":false},{"pmid":"34951318","id":"PMC_34951318","title":"Designing HDAC-PROTACs: lessons learned so far.","date":"2021","source":"Future medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/34951318","citation_count":33,"is_preprint":false},{"pmid":"32007664","id":"PMC_32007664","title":"Emodin and emodin-rich rhubarb inhibits histone deacetylase (HDAC) activity and cardiac myocyte hypertrophy.","date":"2020","source":"The Journal of nutritional biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/32007664","citation_count":33,"is_preprint":false},{"pmid":"37607440","id":"PMC_37607440","title":"The application of PROTAC in HDAC.","date":"2023","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/37607440","citation_count":32,"is_preprint":false},{"pmid":"30715128","id":"PMC_30715128","title":"Dysregulation of HDAC9 Represses Trophoblast Cell Migration and Invasion Through TIMP3 Activation in Preeclampsia.","date":"2019","source":"American journal of hypertension","url":"https://pubmed.ncbi.nlm.nih.gov/30715128","citation_count":32,"is_preprint":false},{"pmid":"26483211","id":"PMC_26483211","title":"Dach2-Hdac9 signaling regulates reinnervation of muscle endplates.","date":"2015","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/26483211","citation_count":32,"is_preprint":false},{"pmid":"28733598","id":"PMC_28733598","title":"Role of HDAC9-FoxO1 Axis in the Transcriptional Program Associated with Hepatic Gluconeogenesis.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28733598","citation_count":31,"is_preprint":false},{"pmid":"32056089","id":"PMC_32056089","title":"HDAC and MAPK/ERK Inhibitors Cooperate To Reduce Viability and Stemness in Medulloblastoma.","date":"2020","source":"Journal of molecular neuroscience : MN","url":"https://pubmed.ncbi.nlm.nih.gov/32056089","citation_count":29,"is_preprint":false},{"pmid":"28176653","id":"PMC_28176653","title":"Multimodal HDAC Inhibitors with Improved Anticancer Activity.","date":"2018","source":"Current cancer drug targets","url":"https://pubmed.ncbi.nlm.nih.gov/28176653","citation_count":29,"is_preprint":false},{"pmid":"35586419","id":"PMC_35586419","title":"Determination of Slow-Binding HDAC Inhibitor Potency and Subclass Selectivity.","date":"2022","source":"ACS medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/35586419","citation_count":29,"is_preprint":false},{"pmid":"32620134","id":"PMC_32620134","title":"Impaired autophagy triggered by HDAC9 in mesenchymal stem cells accelerates bone mass loss.","date":"2020","source":"Stem cell research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/32620134","citation_count":29,"is_preprint":false},{"pmid":"37294406","id":"PMC_37294406","title":"Recent advancement of HDAC inhibitors against breast cancer.","date":"2023","source":"Medical oncology (Northwood, London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/37294406","citation_count":27,"is_preprint":false},{"pmid":"28975602","id":"PMC_28975602","title":"APOL1, CDKN2A/CDKN2B, and HDAC9 polymorphisms and small vessel ischemic stroke.","date":"2017","source":"Acta neurologica Scandinavica","url":"https://pubmed.ncbi.nlm.nih.gov/28975602","citation_count":26,"is_preprint":false},{"pmid":"37279093","id":"PMC_37279093","title":"A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma.","date":"2023","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/37279093","citation_count":26,"is_preprint":false},{"pmid":"27100479","id":"PMC_27100479","title":"HDAC9 regulates ox-LDL-induced endothelial cell apoptosis by participating in inflammatory reactions.","date":"2016","source":"Frontiers in bioscience (Landmark edition)","url":"https://pubmed.ncbi.nlm.nih.gov/27100479","citation_count":26,"is_preprint":false},{"pmid":"26858181","id":"PMC_26858181","title":"Identification of HDAC Inhibitors Using a Cell-Based HDAC I/II Assay.","date":"2016","source":"Journal of biomolecular screening","url":"https://pubmed.ncbi.nlm.nih.gov/26858181","citation_count":26,"is_preprint":false},{"pmid":"39094429","id":"PMC_39094429","title":"Overview of class I HDAC modulators: Inhibitors and degraders.","date":"2024","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/39094429","citation_count":25,"is_preprint":false},{"pmid":"34006836","id":"PMC_34006836","title":"IL-4 inhibits regulatory T cells differentiation by HDAC9-mediated epigenetic regulation.","date":"2021","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/34006836","citation_count":25,"is_preprint":false},{"pmid":"26380023","id":"PMC_26380023","title":"Up-regulation of HDAC9 promotes cell proliferation through suppressing p53 transcription in osteosarcoma.","date":"2015","source":"International journal of clinical and experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26380023","citation_count":25,"is_preprint":false},{"pmid":"36555149","id":"PMC_36555149","title":"Butyrate Lowers Cellular Cholesterol through HDAC Inhibition and Impaired SREBP-2 Signalling.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36555149","citation_count":24,"is_preprint":false},{"pmid":"35747969","id":"PMC_35747969","title":"Recent Progress in Histone Deacetylase (HDAC) 1 Inhibitors as Anticancer Agent.","date":"2022","source":"Current cancer drug targets","url":"https://pubmed.ncbi.nlm.nih.gov/35747969","citation_count":24,"is_preprint":false},{"pmid":"31922233","id":"PMC_31922233","title":"MicroRNA‑936 inhibits the malignant phenotype of retinoblastoma by directly targeting HDAC9 and deactivating the PI3K/AKT pathway.","date":"2020","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/31922233","citation_count":24,"is_preprint":false},{"pmid":"18059609","id":"PMC_18059609","title":"Exercise and MEF2-HDAC interactions.","date":"2007","source":"Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme","url":"https://pubmed.ncbi.nlm.nih.gov/18059609","citation_count":23,"is_preprint":false},{"pmid":"23888962","id":"PMC_23888962","title":"HDAC as a therapeutic target for treatment of endometrial cancers.","date":"2014","source":"Current pharmaceutical design","url":"https://pubmed.ncbi.nlm.nih.gov/23888962","citation_count":23,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":42986,"output_tokens":5698,"usd":0.107214,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":14382,"output_tokens":5382,"usd":0.10323,"stage2_stop_reason":"end_turn"},"total_usd":0.210444,"stage1_batch_id":"msgbatch_01DUPACZi7AAWwuZiUjseQF4","stage2_batch_id":"msgbatch_018yt7chE3f48PEFtDwtj6AE","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2001,\n      \"finding\": \"HDAC9 (and its isoform HDAC9a) contains an HDAC catalytic domain and Flag-tagged HDAC9/HDAC9a possess deacetylase activity in vitro. HDAC9 has multiple alternatively spliced isoforms, including MITR which lacks the catalytic domain. HDAC9 and HDAC9a repress MEF2-mediated transcription.\",\n      \"method\": \"Cloning, in vitro deacetylase activity assay, reporter gene assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct in vitro enzymatic assay with Flag-tagged protein plus transcriptional repression assay, single lab but multiple orthogonal methods\",\n      \"pmids\": [\"11535832\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"MITR (an HDAC9 isoform lacking a catalytic domain) binds directly to the MADS/MEF-2 domain of MEF2 proteins (MEF2D and MEF2A) but not to SRF, and represses MEF2-dependent transcription by recruiting HDAC1.\",\n      \"method\": \"Yeast two-hybrid screen, functional transcription assay, direct binding experiments in Xenopus embryo model\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — yeast two-hybrid plus functional repression assay, HDAC1 recruitment demonstrated, replicated in orthologous system\",\n      \"pmids\": [\"10487760\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"MITR (HDAC9 isoform) interacts with the transcriptional corepressor CtBP through a conserved P-X-D-L-R motif. Mutation of this motif abolishes CtBP interaction and impairs (but does not eliminate) MEF2 transcriptional repression. Residual repressive activity of CtBP-binding mutants is attributable to association with other HDAC family members, revealing CtBP-dependent and -independent mechanisms for transcriptional repression by MITR.\",\n      \"method\": \"Co-immunoprecipitation, mutagenesis of CtBP-binding motif, reporter gene transcription assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — mutagenesis plus Co-IP plus functional reporter assay, multiple orthogonal methods in single study\",\n      \"pmids\": [\"11022042\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"MITR (HDAC9 isoform) is a signal-responsive inhibitor of myogenesis. Phosphorylation of Ser-218 and Ser-448 stimulates binding of 14-3-3 to MITR, disrupts MEF2:MITR interactions, alters nuclear distribution of MITR, and relieves repression of muscle-specific gene expression. A Ser→Ala double mutant acts as a potent repressor of myogenesis, confirming these serines as the regulatory switch.\",\n      \"method\": \"Site-directed mutagenesis, co-immunoprecipitation, immunofluorescence localization, reporter gene assay, myogenic differentiation assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — mutagenesis plus Co-IP plus localization plus functional differentiation assay, multiple orthogonal methods\",\n      \"pmids\": [\"11390982\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"HDAC9 deletion in T regulatory cells (Tregs) leads to increased expression of HSP70, and immunoprecipitation experiments revealed a direct interaction between HSP70 and Foxp3. Inhibition of HSP70 reduced the suppressive functions of HDAC9-/- Tregs, while Tregs overexpressing HSP70 had increased suppressive functions. HDAC9-/- mice were resistant to colitis development.\",\n      \"method\": \"HDAC9 knockout mice, Treg transfer experiments, co-immunoprecipitation (HSP70–Foxp3 interaction), HSP70 inhibition/overexpression assays\",\n      \"journal\": \"Gastroenterology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO with defined cellular phenotype plus Co-IP plus functional rescue experiments, multiple orthogonal methods\",\n      \"pmids\": [\"19879272\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"HDAC9 promotes glioblastoma tumor formation via interaction with TAZ (a Hippo pathway effector). Knockdown of HDAC9 decreased TAZ expression, and overexpression of TAZ in HDAC9-knockdown cells abrogated the effects of HDAC9 silencing on proliferation and tumor formation, placing HDAC9 upstream of TAZ in the EGFR signaling pathway.\",\n      \"method\": \"HDAC9 knockdown, TAZ overexpression rescue, in vitro proliferation assay, in vivo tumor formation assay\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis via rescue experiment plus in vivo validation, single lab\",\n      \"pmids\": [\"25760078\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"HDAC9 inhibits osteoclast differentiation and bone resorption through a mutual suppression loop with PPARγ/RANKL signaling. HDAC9 forms a negative regulatory loop: PPARγ and NF-κB suppress HDAC9 expression, while HDAC9 inhibits PPARγ activity in synergy with SMRT/NCoR corepressors. HDAC9 knockout mice exhibit elevated bone resorption and lower bone mass, and bone marrow transplantation confirms the effect is intrinsic to hematopoietic lineage.\",\n      \"method\": \"HDAC9 knockout mice, bone marrow transplantation, ex vivo osteoclast differentiation assay, HDAC9 overexpression, co-repressor interaction assays\",\n      \"journal\": \"Molecular endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO with bone phenotype, bone marrow transplantation epistasis, mechanistic co-repressor interaction, multiple orthogonal methods\",\n      \"pmids\": [\"25793404\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"MITR (HDAC9c isoform) promotes osteogenesis and inhibits adipogenesis of mesenchymal stem cells by directly interacting with PPARγ-2 in the nucleus of osteoblasts, thereby interrupting PPARγ-2 transcriptional activity and preventing adipogenesis.\",\n      \"method\": \"EZH2-ChIP-on-chip to identify MITR as target, functional differentiation assays, co-immunoprecipitation/interaction studies with PPARγ-2\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP assay plus functional differentiation assay plus interaction studies, single lab\",\n      \"pmids\": [\"21247904\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Dach2 and Hdac9 act collaboratively as activity-regulated transcriptional co-repressors to inhibit reinnervation of denervated mouse skeletal muscle. They inhibit denervation-dependent induction of Myog and Gdf5 gene expression. Myog and Gdf5 appear to stimulate reinnervation through parallel pathways (Myog does not regulate Gdf5 transcription).\",\n      \"method\": \"Dach2 and Hdac9 loss-of-function in mouse skeletal muscle, gene expression analysis, epistasis experiments\",\n      \"journal\": \"Development\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic loss-of-function with defined reinnervation phenotype plus epistasis, single lab\",\n      \"pmids\": [\"26483211\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"HDAC9 regulates hepatic gluconeogenesis by deacetylating FoxO1 (post-translational modification). HDAC9 also regulates gluconeogenic transcription factors PGC-1α, CREB, and GR by altering gene expression via the FoxO1 deacetylation pathway. PGC-1α, CREB and GR are upregulated in response to HDAC9 via FoxO1 deacetylation, and HDAC9-FoxO1 signaling is induced by HCV infection to exaggerate gluconeogenesis.\",\n      \"method\": \"Deacetylation assay of FoxO1, gene expression analysis, FoxO1 binding site analysis in promoters of PGC-1α/CREB/GR, HCV infection model\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct deacetylation of FoxO1 demonstrated plus downstream gene expression, single lab, multiple targets examined\",\n      \"pmids\": [\"28733598\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"HDAC9 forms a ternary complex with the chromatin-remodeling enzyme BRG1 and the lncRNA MALAT1. This HDAC9-MALAT1-BRG1 complex binds chromatin and represses contractile protein gene expression in vascular smooth muscle cells (VSMCs) in association with gain of histone H3-lysine 27 trimethylation. Disruption of Malat1 or Hdac9 restores contractile protein expression, improves aortic mural architecture, and inhibits experimental aneurysm growth.\",\n      \"method\": \"Co-immunoprecipitation of ternary complex, ChIP assay (H3K27me3), loss-of-function (Malat1 or Hdac9 disruption), in vivo aneurysm model\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP of ternary complex plus ChIP plus in vivo loss-of-function with structural phenotype, multiple orthogonal methods\",\n      \"pmids\": [\"29520069\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Increased expression of HDAC9 in human aortic smooth muscle cells promotes calcification and reduces contractility; inhibition of HDAC9 inhibits calcification and enhances cell contractility. HDAC9-knockout mice show 40% reduction in aortic calcification and improved survival in a vascular calcification model.\",\n      \"method\": \"HDAC9 gain- and loss-of-function in human aortic smooth muscle cells, HDAC9 knockout mice in matrix Gla protein-deficient background, calcification assays\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — complementary gain- and loss-of-function in human cells plus in vivo KO model with quantitative phenotype\",\n      \"pmids\": [\"31659325\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"HDAC9 promotes brain ischemic injury by activating IκBα/NF-κB and MAPK signaling pathways. HDAC9 knockout reduces infarct volume, improves neurological function, and suppresses expression of iNOS, COX-2, IL-1β, IL-6, TNF-α, and IL-18 in ischemia/reperfusion injury. In vitro, HDAC9 inhibition-reduced inflammation through the IκBα/NF-κB pathway is reversed by promoting MAPK activity, placing HDAC9 upstream of both pathways.\",\n      \"method\": \"HDAC9 knockout mice, ischemia/reperfusion model, western blot for phosphorylated NF-κB/IκBα/MAPKs, LPS-stimulated cell model with pathway rescue\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO with defined inflammatory phenotype plus epistasis via MAPK rescue, single lab\",\n      \"pmids\": [\"30031609\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"HDAC9 knockdown inhibits cell growth, reduces colony formation, and induces apoptosis and cell cycle arrest in gastric cancer cells, and suppresses tumor growth in vivo. HDAC9 siRNA enhanced antitumor efficacy of cisplatin in gastric cancer.\",\n      \"method\": \"HDAC9 siRNA knockdown, in vitro proliferation/apoptosis/cell cycle assays, in vivo xenograft model\",\n      \"journal\": \"Experimental & molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean KD with defined cellular phenotype in vitro and in vivo, single lab\",\n      \"pmids\": [\"31451695\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"HDAC9 deregulated expression in B cells (Eμ-HDAC9 transgenic mice) promotes development of splenic marginal zone lymphoma and lymphoproliferative disease progressing to DLBCL. HDAC9 appears to contribute to lymphomagenesis by modulating BCL6 activity and p53 tumor suppressor function.\",\n      \"method\": \"Eμ-HDAC9 transgenic mouse model, gene expression profiling, analysis of BCL6 and p53 pathways\",\n      \"journal\": \"Disease models & mechanisms\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — transgenic mouse with defined lymphoma phenotype and pathway analysis, single lab\",\n      \"pmids\": [\"27799148\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"In MCF7 breast cancer cells, HDAC9 overexpression decreased ERα mRNA and protein expression and inhibited ERα transcriptional activity. HDAC9-overexpressing cells were less sensitive to tamoxifen antiproliferative effects, demonstrating a mechanistic role for HDAC9 in antiestrogen resistance through suppression of ERα signaling.\",\n      \"method\": \"HDAC9 overexpression in MCF7 cells, transcriptomic analysis, ERα expression and activity assays, antiproliferative assay\",\n      \"journal\": \"Molecular oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain-of-function with mechanistic ERα pathway analysis plus functional drug response assay, single lab\",\n      \"pmids\": [\"31099456\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"HDAC9 dysregulation in trophoblast cells promotes cell migration and invasion by repressing TIMP3 expression through promoter histone hypoacetylation. HDAC9 knockdown in HTR-8/SVneo cells inhibited migration and invasion, and was associated with upregulation of TIMP3 due to histone hyperacetylation at the TIMP3 promoter detected by ChIP-qPCR.\",\n      \"method\": \"HDAC9 knockdown, transwell migration/invasion assays, ChIP-qPCR of TIMP3 promoter histone acetylation\",\n      \"journal\": \"American journal of hypertension\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — knockdown plus ChIP-qPCR demonstrating direct promoter regulation, single lab\",\n      \"pmids\": [\"30715128\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"IL-4 inhibits regulatory T cell differentiation and Foxp3 expression through a STAT6-dependent mechanism involving HDAC9-mediated histone deacetylation at the Foxp3 locus, decreasing chromatin accessibility and Foxp3 gene transcription.\",\n      \"method\": \"HDAC9 involvement assay, STAT6-dependence experiments, chromatin accessibility assay, pan-HDAC inhibitor rescue, mouse model of allergic airway inflammation\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanistic pathway placement with STAT6 dependence plus functional rescue with HDAC inhibitor, single lab\",\n      \"pmids\": [\"34006836\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"β-hydroxybutyrate (BHB) downregulates HDAC9 expression and suppresses vascular calcification. HDAC9 promotes VSMC calcification via activation of the NF-κB signaling pathway; inhibition of NF-κB attenuated HDAC9-induced VSMC calcification. Both pharmacological inhibition and knockdown of HDAC9 attenuated calcification, while HDAC9 overexpression exacerbated it.\",\n      \"method\": \"RNA-seq, RT-qPCR, western blot, HDAC9 knockdown/overexpression, NF-κB inhibition rescue, calcification assays in VSMCs and aortic rings, in vivo CKD rat and mouse models\",\n      \"journal\": \"The Journal of pathology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — complementary gain- and loss-of-function plus NF-κB epistasis rescue plus in vivo models, multiple orthogonal methods\",\n      \"pmids\": [\"35894849\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"HDAC9 regulates autophagy in bone marrow mesenchymal stem cells (BMMSCs) by controlling H3K9 acetylation at the promoters of autophagic genes ATG7, BECN1, and LC3a/b, thereby affecting lineage differentiation. Elevated HDAC9 in aged mice impairs autophagy and shifts BMMSCs toward adipogenesis; HDAC9 inhibition restored lineage differentiation and improved bone mass.\",\n      \"method\": \"Western blot, ChIP assay (H3K9ac at autophagic gene promoters), TEM/confocal microscopy, micro-CT, HDAC9 inhibitor treatment\",\n      \"journal\": \"Stem cell research & therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP assay demonstrating direct promoter regulation plus functional differentiation and in vivo bone phenotype, single lab\",\n      \"pmids\": [\"32620134\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"HDAC9 knockdown in retinoblastoma cells induces cell cycle arrest at G1 phase with significant decrease in cyclin E2 and CDK2 expression, inhibits proliferation in vitro, and inhibits tumor growth in vivo.\",\n      \"method\": \"HDAC9 knockdown, cell cycle analysis (flow cytometry), western blot for cyclin E2/CDK2, xenograft tumor model\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean KD with defined cell cycle arrest phenotype and mechanistic downstream targets identified, single lab\",\n      \"pmids\": [\"27033599\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"HDAC9 epigenetically represses p53 transcription in osteosarcoma cells by binding to the p53 proximal promoter region, as demonstrated by ChIP assay. HDAC9 overexpression promoted cell proliferation and invasion.\",\n      \"method\": \"ChIP assay (HDAC9 binding to p53 promoter), HDAC9 overexpression, proliferation and invasion assays\",\n      \"journal\": \"International journal of clinical and experimental medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP assay demonstrating direct promoter binding plus functional overexpression phenotype, single lab\",\n      \"pmids\": [\"26380023\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"HDAC9 is a class IIa histone deacetylase that shuttles between nucleus and cytoplasm, represses MEF2-dependent transcription through direct MEF2 binding and recruitment of corepressors (CtBP, HDAC1, SMRT/NCoR), is regulated by phosphorylation-dependent 14-3-3 binding that exports it from the nucleus, deacetylates non-histone substrates including FoxO1 to regulate gluconeogenesis, forms a ternary repressive complex with BRG1 and MALAT1 lncRNA to silence contractile genes in vascular smooth muscle cells, promotes vascular calcification via NF-κB activation, controls bone remodeling by suppressing osteoclastogenesis through a PPARγ/RANKL loop, regulates T regulatory cell function by modulating Foxp3 locus histone acetylation, and controls autophagic gene expression via H3K9 acetylation at promoters of ATG7, BECN1, and LC3a/b.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"HDAC9 is a class IIa histone deacetylase that functions as a signal-responsive transcriptional repressor, controlling differentiation programs in muscle, immune, skeletal, and vascular lineages through both catalytic deacetylation and corepressor scaffolding [#0, #3]. Its founding activity is repression of MEF2-dependent transcription: HDAC9 and its catalytically inactive splice isoform MITR bind directly to the MADS/MEF2 domain of MEF2 proteins and recruit corepressors including HDAC1 and CtBP through a conserved P-X-D-L-R motif, with CtBP-dependent and -independent repression operating in parallel [#0, #1, #2]. This repression is switched off by phosphorylation of Ser-218 and Ser-448, which promotes 14-3-3 binding, disrupts the MEF2 interaction, alters nuclear distribution, and relieves silencing of muscle-specific genes [#3]. Beyond histone substrates, HDAC9 deacetylates the transcription factor FoxO1 to drive hepatic gluconeogenic gene expression (PGC-1\\u03b1, CREB, GR) [#9], and it acts at chromatin through targeted histone deacetylation—repressing TIMP3 and the Foxp3 locus, and controlling H3K9 acetylation at autophagy gene promoters (ATG7, BECN1, LC3a/b) to govern lineage differentiation [#16, #17, #19]. In vascular smooth muscle cells HDAC9 assembles a ternary repressive complex with the chromatin remodeler BRG1 and the lncRNA MALAT1 to silence contractile genes and, via NF-\\u03baB activation, promotes vascular calcification, driving aneurysm and calcification pathology in vivo [#10, #11, #18]. HDAC9 also restrains osteoclastogenesis and adipogenesis through a mutually suppressive loop with PPAR\\u03b3/RANKL signaling in concert with SMRT/NCoR corepressors [#6, #7]. Across multiple cancers HDAC9 acts as a pro-tumorigenic regulator, repressing p53 and ER\\u03b1 and supporting proliferation and survival [#13, #15, #21].\",\n  \"teleology\": [\n    {\n      \"year\": 1999,\n      \"claim\": \"Established that an HDAC9 isoform represses MEF2-dependent transcription by directly engaging MEF2 and recruiting deacetylase machinery, defining HDAC9 as a MEF2 corepressor.\",\n      \"evidence\": \"Yeast two-hybrid, direct binding and transcription assays in Xenopus embryos (MITR\\u2013MEF2D/A binding, HDAC1 recruitment)\",\n      \"pmids\": [\"10487760\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not establish the catalytic contribution of full-length HDAC9\", \"Physiological gene targets of MEF2 repression not defined\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Defined HDAC9 as a catalytically active deacetylase with multiple isoforms (including catalytic-domain-lacking MITR) and confirmed MEF2 repression, while delineating CtBP-dependent and -independent repression routes.\",\n      \"evidence\": \"Cloning, in vitro deacetylase assays, CtBP-motif mutagenesis, Co-IP, reporter assays\",\n      \"pmids\": [\"11535832\", \"11022042\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endogenous histone substrates not mapped\", \"Relative contributions of catalytic vs scaffolding repression unresolved\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Identified the phosphorylation/14-3-3 switch that converts HDAC9/MITR from repressor to permissive state, explaining how external signals release MEF2-dependent muscle genes.\",\n      \"evidence\": \"Site-directed mutagenesis of Ser-218/Ser-448, Co-IP, immunofluorescence, myogenic differentiation assays\",\n      \"pmids\": [\"11390982\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Kinases phosphorylating these serines not identified in this work\", \"Mechanism of nuclear redistribution not structurally resolved\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Linked HDAC9 to regulatory T cell suppressive function via HSP70 and Foxp3, extending its repressor role into immune tolerance.\",\n      \"evidence\": \"HDAC9 knockout mice, Treg transfer, HSP70\\u2013Foxp3 Co-IP, HSP70 inhibition/overexpression, colitis model\",\n      \"pmids\": [\"19879272\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct deacetylation target in this axis not defined\", \"Whether effect is catalytic or scaffolding unclear\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Showed HDAC9/MITR directs mesenchymal lineage choice toward osteogenesis by directly antagonizing PPAR\\u03b3-2 transcriptional activity.\",\n      \"evidence\": \"EZH2 ChIP-on-chip, differentiation assays, PPAR\\u03b3-2 interaction studies\",\n      \"pmids\": [\"21247904\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Interaction not validated by reciprocal Co-IP\", \"Single lab\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Established HDAC9 as a suppressor of osteoclastogenesis through a mutual PPAR\\u03b3/RANKL feedback loop acting with SMRT/NCoR, demonstrated to be hematopoietic-intrinsic.\",\n      \"evidence\": \"HDAC9 KO mice, bone marrow transplantation, ex vivo osteoclast differentiation, corepressor interaction assays\",\n      \"pmids\": [\"25793404\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct chromatin targets in osteoclast precursors not mapped\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Extended HDAC9 corepressor activity to neuromuscular plasticity, showing collaboration with Dach2 to suppress reinnervation genes Myog and Gdf5.\",\n      \"evidence\": \"Loss-of-function in mouse skeletal muscle, gene expression and epistasis analysis\",\n      \"pmids\": [\"26483211\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs indirect regulation of Myog/Gdf5 promoters not resolved\", \"Molecular nature of Dach2\\u2013HDAC9 cooperation undefined\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Implicated HDAC9 as pro-tumorigenic in multiple contexts—upstream of TAZ in glioblastoma, repressing p53 at its promoter in osteosarcoma, and driving retinoblastoma cell cycle progression.\",\n      \"evidence\": \"Knockdown/overexpression, rescue epistasis, ChIP of p53 promoter, cell cycle/xenograft assays\",\n      \"pmids\": [\"25760078\", \"26380023\", \"27033599\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs indirect TAZ regulation unclear\", \"Each finding single lab and tumor-type specific\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Demonstrated that HDAC9 overexpression in B cells drives lymphomagenesis through BCL6 and p53 pathway modulation.\",\n      \"evidence\": \"E\\u03bc-HDAC9 transgenic mice, gene expression profiling, BCL6/p53 pathway analysis\",\n      \"pmids\": [\"27799148\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct molecular targets of HDAC9 in B cells not defined\", \"Catalytic requirement not tested\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identified a non-histone substrate by showing HDAC9 deacetylates FoxO1 to amplify hepatic gluconeogenic gene programs, a pathway co-opted during HCV infection.\",\n      \"evidence\": \"FoxO1 deacetylation assay, gene expression of PGC-1\\u03b1/CREB/GR, FoxO1 promoter binding analysis, HCV model\",\n      \"pmids\": [\"28733598\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct deacetylation residues not mapped\", \"Single lab\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Defined a ternary HDAC9\\u2013BRG1\\u2013MALAT1 chromatin complex that silences VSMC contractile genes with H3K27me3 gain, linking HDAC9 to aneurysm pathology.\",\n      \"evidence\": \"Co-IP of ternary complex, ChIP for H3K27me3, Malat1/Hdac9 loss-of-function, in vivo aneurysm model\",\n      \"pmids\": [\"29520069\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry and assembly order of the complex unresolved\", \"Whether HDAC9 catalytic activity is required not isolated\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Placed HDAC9 upstream of both I\\u03baB\\u03b1/NF-\\u03baB and MAPK signaling in driving ischemic brain inflammatory injury.\",\n      \"evidence\": \"HDAC9 KO mice, ischemia/reperfusion model, phospho-protein western blots, LPS cell model with MAPK rescue\",\n      \"pmids\": [\"30031609\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct molecular link between HDAC9 and these signaling nodes undefined\", \"Single lab\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Established HDAC9 as a driver of vascular calcification with reduced contractility, confirmed by complementary gain/loss-of-function and in vivo KO.\",\n      \"evidence\": \"Gain/loss-of-function in human aortic SMCs, HDAC9 KO in MGP-deficient mice, calcification assays\",\n      \"pmids\": [\"31659325\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanistic chromatin targets in calcifying SMCs not detailed in this study\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Extended HDAC9's promoter-level repression to trophoblast invasion (TIMP3) and antiestrogen resistance (ER\\u03b1) and to gastric cancer growth and chemosensitivity.\",\n      \"evidence\": \"Knockdown/overexpression, ChIP-qPCR of TIMP3 promoter acetylation, ER\\u03b1 activity assays, gastric xenografts with cisplatin\",\n      \"pmids\": [\"30715128\", \"31099456\", \"31451695\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"ER\\u03b1 regulation mechanism (direct vs indirect) not fully resolved\", \"Each context single lab\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Showed HDAC9 controls autophagy gene expression via H3K9 deacetylation at ATG7, BECN1, and LC3a/b promoters, coupling its activity to age-related skeletal stem cell lineage shifts.\",\n      \"evidence\": \"ChIP for H3K9ac at autophagic gene promoters, TEM/confocal, micro-CT, HDAC9 inhibitor treatment in aged mice\",\n      \"pmids\": [\"32620134\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct binding of HDAC9 to these promoters vs indirect effect not fully separated\", \"Single lab\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Positioned HDAC9 downstream of IL-4/STAT6 in deacetylating the Foxp3 locus to limit chromatin accessibility and regulatory T cell differentiation.\",\n      \"evidence\": \"STAT6-dependence experiments, chromatin accessibility assays, pan-HDAC inhibitor rescue, allergic airway model\",\n      \"pmids\": [\"34006836\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Pan-HDAC inhibitor not HDAC9-specific\", \"Direct recruitment mechanism to Foxp3 locus undefined\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Confirmed NF-\\u03baB activation as the effector pathway for HDAC9-driven VSMC calcification and identified \\u03b2-hydroxybutyrate as a suppressor of HDAC9 expression.\",\n      \"evidence\": \"RNA-seq, gain/loss-of-function, NF-\\u03baB inhibition rescue, calcification assays, CKD rat/mouse models\",\n      \"pmids\": [\"35894849\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which HDAC9 activates NF-\\u03baB not molecularly defined\", \"Direct chromatin targets in this axis unmapped\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Whether HDAC9's many context-specific phenotypes depend on catalytic deacetylation versus corepressor scaffolding, and the direct genomic and non-histone substrate repertoire in each tissue, remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No catalytic-dead vs scaffolding-only structure-function dissection across tissues\", \"Genome-wide direct HDAC9 binding map absent\", \"Non-histone substrate spectrum beyond FoxO1 uncharacterized\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 9]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [1, 2, 10, 21]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [0]},\n      {\"term_id\": \"GO:0042393\", \"supporting_discovery_ids\": [16, 19]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [3, 7]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [3]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 1, 10]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [10, 16, 19]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [3, 6, 7]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [4, 17]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [19]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [5, 12, 18]}\n    ],\n    \"complexes\": [\"HDAC9-MALAT1-BRG1 ternary repressive complex\"],\n    \"partners\": [\"MEF2D\", \"MEF2A\", \"HDAC1\", \"CtBP\", \"YWHA(14-3-3)\", \"PPARG\", \"BRG1\", \"FOXO1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}